Compare CBL & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBL | STOK |
|---|---|---|
| Founded | 1978 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1995 | 2019 |
| Metric | CBL | STOK |
|---|---|---|
| Price | $53.90 | $28.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $45.00 | $39.20 |
| AVG Volume (30 Days) | 179.7K | ★ 678.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.00% | N/A |
| EPS Growth | ★ 132.09 | 92.73 |
| EPS | ★ 2.95 | N/A |
| Revenue | ★ $578,373,000.00 | $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $77.49 |
| P/E Ratio | $18.26 | ★ N/A |
| Revenue Growth | 12.18 | ★ 404.50 |
| 52 Week Low | $28.05 | $20.32 |
| 52 Week High | $60.40 | $40.22 |
| Indicator | CBL | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 42.80 | 38.77 |
| Support Level | $53.64 | $28.02 |
| Resistance Level | $55.88 | $33.61 |
| Average True Range (ATR) | 1.28 | 1.21 |
| MACD | -0.15 | -0.25 |
| Stochastic Oscillator | 42.76 | 17.50 |
CBL & Associates Properties Inc is a real estate investment trust. The company engages in the ownership, development, acquisition, leasing, management and operation of regional shopping malls, outlet centers, lifestyle centers, open-air centers and other properties. CBL's sales predominantly derive from leasing arrangements with retail tenants. The company also generates revenue from management and development fees, as well as sales of its real estate assets. CBL expands its portfolio of assets through activities such as redevelopment, renovation, and expansion.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.